Retatrutide (LY3437943): Triple-Agonist Pharmacology and Phase 2 Trial Data

Retatrutide — Eli Lilly compound code LY3437943 — is the first triple-receptor agonist in the incretin class to reach Phase 2 trials. It activates GIP, GLP-1, and glucagon receptors simultaneously. The triple mechanism produced a body weight reduction signal in Phase 2 that exceeds what either single-agonist (semaglutide) or dual-agonist (tirzepatide) compounds achieved in their pivotal trials, making it the most potent weight loss signal reported in a randomised controlled trial in this class to date.

This article walks through the receptor pharmacology, the two Phase 2 trials that defined the dosing window, and where Retatrutide sits relative to the rest of the GLP-1 class for research purposes.

Why the triple mechanism matters

The incretin-class progression has been a story of adding receptor agonism, not subtracting it:

| Compound | Class | Receptors | Trial-stage weight loss | |---|---|---|---| | Semaglutide | Single agonist | GLP-1 | ~15% at 68 weeks (STEP-1) | | Tirzepatide | Dual agonist | GIP + GLP-1 | ~21% at 72 weeks (SURMOUNT-1) | | Retatrutide | Triple agonist | GIP + GLP-1 + glucagon | ~24% at 48 weeks (Phase 2) |

Each receptor adds a distinct mechanism:

GLP-1 agonism is the foundational incretin pathway. It slows gastric emptying, suppresses appetite via central hypothalamic signalling, and improves glycaemic control through glucose-dependent insulin secretion. Semaglutide and the rest of the GLP-1 class converge on this axis.

GIP agonism adds a second incretin pathway. The exact contribution of GIP to weight loss versus glycaemic control remains debated — GIP receptor knockout models initially suggested GIP antagonism might be protective against obesity, but tirzepatide's clinical data with GIP agonism contradicted that hypothesis. The current working model: GIP agonism enhances GLP-1's anorectic effect and improves the GI tolerability profile at higher doses by modulating central nausea pathways.

Glucagon receptor agonism is the mechanistic differentiator for Retatrutide. Glucagon increases hepatic glucose output (the classic counter-regulatory hormone effect) but also stimulates resting energy expenditure by activating thermogenesis in brown adipose tissue and increasing fatty acid oxidation. In the Retatrutide development programme, this is the pathway responsible for the extra body weight reduction beyond what GIP+GLP-1 alone produced in tirzepatide.

The trade-off: glucagon agonism risks hyperglycaemia if unopposed. Retatrutide's molecular design balances glucagon agonism against the glucose-lowering effect of GLP-1 + GIP — net effect on HbA1c in the Phase 2 type 2 diabetes trial was placebo-superior reduction ², indicating the balance is empirically correct.

Phase 2 obesity trial — Jastreboff et al. 2023

The Jastreboff trial published in NEJM is the primary reference point for Retatrutide's body weight signal ¹. Key parameters:

| Parameter | Value | |---|---| | n | 338 adults, BMI ≥30 (or ≥27 with weight-related condition), without diabetes | | Doses tested | 1, 4, 8, 12 mg weekly SC | | Trial duration | 48 weeks | | Primary endpoint | % change in body weight at 24 and 48 weeks | | 12 mg result at 48 weeks | ~24.2% body weight reduction | | 8 mg result at 48 weeks | ~22.8% body weight reduction | | Placebo at 48 weeks | ~2.1% reduction |

The dose-response was linear-ish from 1 mg through 12 mg with no plateau at the high end — meaning the trial may not have reached Retatrutide's full ceiling effect. The titration protocol (2 mg weeks 1-4, 4 mg weeks 5-8, 8 mg weeks 9-12, 12 mg maintenance) is the published reference dosing.

GI adverse events were the dominant tolerability issue, with rates roughly proportional to dose. Approximately 80% of participants at the 12 mg dose reported at least one GI event (nausea, vomiting, or diarrhoea), though most were classified as mild-to-moderate. Discontinuation rates due to adverse events were single-digit percentage even at the top dose.

Phase 2 type 2 diabetes trial — Rosenstock et al. 2023

The companion Phase 2 trial in patients with type 2 diabetes was published in The Lancet ². This trial used dulaglutide 1.5 mg as the active comparator (rather than placebo-only) and measured both HbA1c and body weight as co-primary endpoints.

Retatrutide produced larger HbA1c reductions than dulaglutide at all doses tested, with the 12 mg dose producing an absolute HbA1c reduction of approximately 2.0%-2.16% from baseline at 36 weeks. Body weight reduction was again dose-dependent and substantially larger than dulaglutide.

The two-trial design (obesity in NEJM, diabetes in Lancet) is the standard incretin-class Phase 2 pattern Lilly has used for tirzepatide — establish efficacy in both populations before Phase 3 commits to specific indications.

Where Retatrutide sits for research purposes

For body-composition research protocols, Retatrutide is the strongest signal in the class but also carries the most uncertainty:

• Phase 3 trials are ongoing — full safety profile, durability of weight loss, and cardiovascular outcomes are not yet published
• Long-term safety beyond 48 weeks unknown — the obesity trial duration was the longest published, and ~24% weight loss at one year may or may not maintain at two years
• Glucagon receptor agonism is novel at this scale — the long-term effect of sustained glucagon agonism on liver fat, glucose homeostasis, and cardiovascular outcomes will only become clear with Phase 3 data
• Comparator data limited — the obesity trial used placebo, the diabetes trial used dulaglutide; no head-to-head against tirzepatide has been published

The Jastreboff and Rosenstock Phase 2 papers are the current best evidence. Researchers should treat them as the reference for dosing protocol, expected effect size, and safety signal — and watch the Phase 3 readouts (SURMOUNT-style trials are running) as they publish over 2026-2027.

Compared to the rest of the GLP-1 class

For practical research protocol design, Retatrutide pairs with Semaglutide and Tirzepatide as the three reference compounds in the modern incretin class. Each has a distinct evidence base and use case:

• Semaglutide — deepest Phase 3 evidence, including cardiovascular outcomes (SELECT trial). Established safety profile. Best documented baseline for any incretin research.
• Tirzepatide — best Phase 3 weight loss data (SURMOUNT-1, SURMOUNT-3), strong type 2 diabetes data (SURPASS series). Established as the dual-agonist reference.
• Retatrutide — strongest Phase 2 weight loss signal in the class. Limited safety database. Emerging compound — the next-generation reference once Phase 3 completes.

See the Semaglutide vs Tirzepatide clinical trial comparison for the depth of evidence on the established two compounds, and the Best Peptides for Fat Loss buyer guide for the broader research-compound landscape including AOD-9604 and 5-Amino-1MQ.

Citations

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. PMID: 37385280